Xeris Biopharma Holdings, Inc. (ticker: XERS) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of XERS's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. XERS reported $83.13M in revenue and $2.23M for the period ending 2026-03-31, with operating cash flow of $9.87M. Cash and equivalents stood at $111.75M (up 91.2% year-over-year). Total assets of $392.01M exceed total liabilities of $379.00M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
XERS SEC Filings
Full cached SEC EDGAR filing history for XERS, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.